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Background
While passively administered broadly neutralizing mono-
clonal antibodies (bnmAbs) prevented SHIV acquisition,
polyclonal Abs with high neutralizing titers provided only
moderate protection in primates.
Methods
We tested whether passive immunization with polyclonal
IgG raised in rhesus monkeys (RMs) with chronic clade C
SHIV infection, termed SHIVIG, could protect RMs
against multiple low-dose intrarectal challenges with the
R5 tier-2 SHIV-2873Nip carrying an HIV clade C envelope
heterologous to the viruses/envelopes against which the
IgG responses had been elicited. We compared in vitro
SHIVIG characteristics with in vivo protection.
Results
In vitro, SHIVIG demonstrated binding to SIV Gag, HIV
Tat and Env of different clades, contained b12 and 4E10-
like Abs and neutralized tier-1 and 2 viruses, including
SHIV-2873Nip. NK-cell depletion decreased neutralizing
activity in PBMC assays 20-fold. SHIVIG completely
inhibited viral replication by ADCVI assay, but showed
only 35% target-cell killing by ADCC assay.
Four groups of RMs were given SHIVIG at different
doses: Group 1 (400 mg/kg), Group 2 (675 mg/kg), Group
3 (25 mg/kg) and Group 4 (none; virus-only control) fol-
lowed by weekly low-dose challenges with SHIV-2873Nip.
All controls and all SHIVIG-treated animals became sys-
temically infected. RMs given 400 mg/kg of SHIVIG
showed significantly lower peak viral RNA loads compared
to controls. Surprisingly, single-genome analysis revealed a
significant increase in the number of transmitted variants
in Group 3 compared to controls (P=0.032), suggesting
increased acquisition. Complement-mediated Ab-depen-
dent enhancement of infection (C’- A D E )a tl o wS H I V I G
concentrations was observed in vitro.
Conclusion
Lack of protection and possibly increased acquisition
has been reported for a passive immunization study that
tested the efficacy of HIV hyperimmune globulin in pre-
venting infection in Ugandan infants born to HIV-posi-
tive women (Onyango-Makumbi, JAIDS 2011). Thus,
our primate model data paralleled clinical phase III
results and suggest that polyclonal anti-HIV-1 Abs play
a dual role upon virus encounter.
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